Skip to content

Return on equity at other companies

Pfizer logo
PfizerPFE
10.6%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
14.5%-1.4pp
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
9.1%+2.8pp
Insmed logo
InsmedINSM
-294.5%
Capricor Therapeutics logo
Capricor TherapeuticsCAPR
-56.4%-11.3pp
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
24.5%-4.6pp

Other financials

Income statement

See full
Revenue$730.8M-1.9%
Operating income-$300.4M-961%
Net income$331.0M+174%
EPS (diluted)-$4.60-1,343%

Balance sheet

See full
Cash & equivalents$464.5M+92.8%
Total debt$198.5M-3.4%
Total equity$1.5B+31.7%
Total assets$3.2B-8.3%

Cash flow

See full
Operating cash flow-$202.7M+65.3%
CapEx$2.1M-95.2%
Free cash flow-$204.8M+67.3%

Valuation

See full
Market cap$1.82B-63.1%
Enterprise value$1.56B-67.2%
P/S0.8×

Profitability

See full
Operating margin-50.8%-1.6pp
Net margin4.6%+2.4pp
FCF margin-28.7%-9.2pp

Returns & leverage

See full
Debt / equity0.1×0.0×
Current ratio4.6×+0.6×

Where this comes from

Calculated from Sarepta Therapeutics, Inc.’s reported figures.

Based on trailing twelve months.

The official record: Sarepta Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sarepta Therapeutics, Inc.'s return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Sarepta Therapeutics, Inc.'s return on equity?
Sarepta Therapeutics, Inc. (SRPT) reported return on equity of -23.6% in Q1 2025.
How has Sarepta Therapeutics, Inc.'s return on equity changed year-over-year?
Sarepta Therapeutics, Inc.'s return on equity decreased by 587.2% year-over-year, from -3.4% to -23.6%.
What is the long-term trend for Sarepta Therapeutics, Inc.'s return on equity?
Over 4 years (2020 to 2024), Sarepta Therapeutics, Inc.'s return on equity has grown at a -27.2% compound annual growth rate (CAGR), from -70.1% to 19.7%.
What does return on equity mean?
Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.